Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a global public health crisis. Some patients who have recovered from COVID-19 subsequently test positive again for SARS-CoV-2 RNA after discharge from hospital. How such retest-positive (RTP) patients become infected again is not known. In this study, 30 RTP patients, 20 convalescent patients, and 20 healthy controls were enrolled for the analysis of immunological characteristics of their peripheral blood mononuclear cells. We found that absolute numbers of CD4+ T cells, CD8+ T cells, and natural killer cells were not substantially decreased in RTP patients, but the expression of activation markers on these cells was significantly reduced. The percentage of granzyme B-producing T cells was also lower in RTP patients than in convalescent patients. Through transcriptome sequencing, we demonstrated that high expression of inhibitor of differentiation 1 (ID1) and low expression of interferon-induced transmembrane protein 10 (IFITM10) were associated with insufficient activation of immune cells and the occurrence of RTP. These findings provide insight into the impaired immune function associated with COVID-19 and the pathogenesis of RTP, which may contribute to a better understanding of the mechanisms underlying RTP.

[1]  P. Daszak,et al.  Science, not speculation, is essential to determine how SARS-CoV-2 reached humans , 2021, The Lancet.

[2]  P. Peng,et al.  Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial , 2021, International Immunopharmacology.

[3]  Jingkun Qin,et al.  Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status , 2021, Journal of Autoimmunity.

[4]  G. Gao,et al.  Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.

[5]  Young Keun Kim,et al.  PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19 , 2020, Immunity.

[6]  Hui Yang,et al.  SARS-CoV-2 infection and the antiviral innate immune response , 2020, Journal of molecular cell biology.

[7]  J. C. Cohen Tervaert,et al.  Natural Killer Cell Dysfunction and Its Role in COVID-19 , 2020, International journal of molecular sciences.

[8]  B. Reinius,et al.  Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.

[9]  C. Dong,et al.  Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients , 2020, Frontiers in Immunology.

[10]  Jiyuan Zhang,et al.  Single-cell landscape of immunological responses in patients with COVID-19 , 2020, Nature Immunology.

[11]  L. Ren,et al.  Activation and evasion of type I interferon responses by SARS-CoV-2 , 2020, Nature Communications.

[12]  C. Yao,et al.  Cell type-specific immune dysregulation in severely ill COVID-19 patients , 2020, medRxiv.

[13]  G. Gao,et al.  Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients , 2020, Immunity.

[14]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[15]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[16]  F. Vély,et al.  Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19 , 2020, Cellular & Molecular Immunology.

[17]  O. Pybus,et al.  Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR , 2020, EBioMedicine.

[18]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[19]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[20]  C. Akdis,et al.  Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status , 2020, Allergy.

[21]  D. Tang,et al.  The hallmarks of COVID-19 disease , 2020, PLoS pathogens.

[22]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[23]  Slobodan Paessler,et al.  Antiviral activities of type I interferons to SARS-CoV-2 infection , 2020, Antiviral Research.

[24]  H. Hou,et al.  The laboratory tests and host immunity of COVID-19 patients with different severity of illness. , 2020, JCI insight.

[25]  Binqing Fu,et al.  Why tocilizumab could be an effective treatment for severe COVID-19? , 2020, Journal of Translational Medicine.

[26]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[27]  Yang Liu,et al.  Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test , 2020, medRxiv.

[28]  Hongyang Wang,et al.  Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing , 2020, Cell Discovery.

[29]  H. Shan,et al.  Prolonged presence of SARS-CoV-2 viral RNA in faecal samples , 2020, The Lancet Gastroenterology & Hepatology.

[30]  Z. Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[31]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[32]  W. Ni,et al.  Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase , 2020, medRxiv.

[33]  Lei Liu,et al.  Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury , 2020, National science review.

[34]  P. Hsu,et al.  Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus , 2020, Cellular & Molecular Immunology.

[35]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[36]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[37]  B. Győrffy,et al.  Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing. , 2020, Cancer discovery.

[38]  Yong-xiang Wang,et al.  Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. , 2019, Journal of hepatology.

[39]  T. Crompton,et al.  The IFITM protein family in adaptive immunity , 2019, Immunology.

[40]  G. Cheng,et al.  Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation , 2019, Cell reports.

[41]  R. Sun,et al.  HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma , 2019, Cellular & Molecular Immunology.

[42]  J. Schoggins.  Interferon-Stimulated Genes: What Do They All Do? , 2019, Annual review of virology.

[43]  D. Finlay,et al.  Immunometabolism and natural killer cell responses , 2019, Nature Reviews Immunology.

[44]  P. Loke,et al.  IFN-I and IL-22 mediate protective effects of intestinal viral infection , 2019, Nature Microbiology.

[45]  M. Kurachi.  CD8+ T cell exhaustion , 2019, Seminars in Immunopathology.

[46]  E. Munari,et al.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications , 2019, Cellular & Molecular Immunology.

[47]  D. Farber,et al.  Human T Cell Development, Localization, and Function throughout Life. , 2018, Immunity.

[48]  Hyunggee Kim,et al.  Inhibition of ID1–BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy , 2017, Clinical Cancer Research.

[49]  T. Watts,et al.  Dichotomous Expression of TNF Superfamily Ligands on Antigen‐Presenting Cells Controls Post‐priming Anti‐viral CD4+ T Cell Immunity , 2017, Immunity.

[50]  C. Rolfo,et al.  The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. , 2017, Cancer letters.

[51]  Y. Ye,et al.  NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B , 2016, Scientific Reports.

[52]  M. Diamond,et al.  The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses , 2016, Journal of Virology.

[53]  J. Wolchok,et al.  Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation , 2015, Nature Communications.

[54]  M. Farzan,et al.  IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. , 2014, Annual review of virology.

[55]  A. Iavarone,et al.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness , 2014, Nature Reviews Cancer.

[56]  M. Diamond,et al.  The broad-spectrum antiviral functions of IFIT and IFITM proteins , 2012, Nature Reviews Immunology.

[57]  W. Gerald,et al.  Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. , 2006, Cancer research.

[58]  Guohong Deng,et al.  TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. , 2019, Journal of hepatology.

[59]  W. Gerald,et al.  Reassessment of Id 1 Protein Expression in Human Mammary , Prostate , and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id 1 Antibody , 2006 .

[60]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.